Utility of ANA in hospitalized patients with headache and suspected systemic autoimmune disease
Headache: The Journal of Head and Face Pain · 2026-06 · 66 (6) · 1244-1249
DOI: 10.1111/head.70063 ↗At a glance
Journal article in Headache: The Journal of Head and Face Pain, published online on 2026-04-09. Written by Erez Magiel and 7 co-authors. Institution: Neurological Department, Sheba Medical Center, Ramat Gan, Israel. Major MEDLINE topics: Antibodies, Antinuclear, Autoimmune Diseases, Headache. 13 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Objective
This study evaluates antinuclear antibody (ANA) test performance in identifying rheumatologic conditions as the source of the headache.
Background
ANA testing is widely used to screen for autoimmune diseases in patients with headaches, but its diagnostic utility remains unclear.
Methods
In this retrospective analytic, cross‐sectional study, 539 patients hospitalized with headache at Sheba Medical Center (2007–2022) underwent ANA testing. Data included demographics, ANA titers and patterns, C‐reactive protein levels, and rheumatologic diagnoses confirmed at discharge or follow‐up. Statistical analyses compared clinical features between groups with and without rheumatologic diagnoses.
Results
Rheumatologic diagnoses were confirmed in 9.6% ( n = 52). Affected patients were older (median 54.7 vs. 41.9 years, p < 0.001), had higher ANA positivity (76.9% vs. 41.9%, p < 0.001), and had elevated titers ( p = 0.003). Homogeneous (17.5% vs. 5.4%) and mixed (25.0% vs. 14.2%) staining patterns were more frequent in rheumatologic cases ( p = 0.02). C‐reactive protein levels lacked diagnostic utility except in vasculitis and giant cell arteritis. Notably, 83.6% of ANA‐positive patients had no rheumatologic diagnosis.
Conclusions
Whereas ANA positivity correlates with rheumatologic disease in patients with headache, its low positive predictive value limits utility as a standalone screening tool. Though age was a differentiator in ANA positivity, our findings support that ANA testing should be performed only when there is clinical suspicion for systemic autoimmune disease, regardless of patient age. Overuse may lead to false positives, unnecessary investigations, and resource strain. Clinical context rather than serology should guide autoimmune evaluation in headache management.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Neurological Department, Sheba Medical Center, Ramat Gan, Israel.
- Dina Recanati School of Medicine, Reichman University, Herzliya, Israel.
- Gertner Institute Sheba Medical Center, Ramat-Gan, Israel.
- Department of Neurology and Neurosurgery, Faculty of Health and Medical Sciences, Tel Aviv University, Tel Aviv, Israel.
- Department of Rheumatology, Faculty of Health and Medical Sciences, Tel Aviv University, Tel Aviv, Israel.
- Department of Medicine "B" and Zabludowicz Center of Autoimmune Diseases, Sheba Medical Center, Ramat Gan, Israel.
ORCID profiles: Erez Magiel, Roni Sharon
Cite
APA
Magiel, E., Roitman, M. S., Pflantzer, B., Dagan, R. L., Sharon, R., Watad, A., Maggio, N., & Anis, S. (2026). Utility of ANA in hospitalized patients with headache and suspected systemic autoimmune disease. Headache: The Journal of Head and Face Pain, 66(6), 1244-1249. https://doi.org/10.1111/head.70063
Vancouver
Magiel E, Roitman MS, Pflantzer B, Dagan RL, Sharon R, Watad A, et al. Utility of ANA in hospitalized patients with headache and suspected systemic autoimmune disease. Headache: The Journal of Head and Face Pain. 2026;66(6):1244-1249. doi:10.1111/head.70063
BibTeX
@article{Magiel2026,
author = {Magiel, Erez and Roitman, Melanie Shanie and Pflantzer, Barak and Dagan, Roni Loebenstein and Sharon, Roni and Watad, Abdualla and Maggio, Nicola and Anis, Saar},
title = {Utility of ANA in hospitalized patients with headache and suspected systemic autoimmune disease},
journal = {Headache: The Journal of Head and Face Pain},
year = {2026},
volume = {66},
number = {6},
pages = {1244--1249},
doi = {10.1111/head.70063}
}
EUVIMED